MGC Pharmaceuticals Ltd
Compliance Release - Application for Admission to Trading
2 August 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ("MGC Pharma" or the "Company") is applying for admission to the Financial Conduct Authority's Official List and to trading on the Main Market of London Stock Exchange plc ("Admission) of 87,353,469 fully paid Ordinary Shares ("Shares") previously issued by MGC Pharma. Admission of the Shares is expected to take place at 8:00am (British Summer Time) on 9 August 2023.
Details of the 87,353469 Shares for which these applications have been lodged are as follows:
· 21,511,545 shares issued to Mercer in 2022 pursuant to a financing agreement.
· 65,841,924 shares issued in 2022 as consideration for the 40% acquisition of ZAM Software Limited.
The Shares are already quoted on the ASX and application for Admission will not affect the Total Voting Rights in the Company.
-Ends-
Authorised for release by the Managing Director, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6382 3390 |
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceutica
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.